Swedish Orphan Biovitrum AB

About Us

Sobi is a global biopharma company unlocking the potential of breakthrough innovations, transforming everyday life for people living with rare diseases. Sobi has approximately 2,000 employees across Europe, North America, the Middle East, Asia and Australia. In 2025, revenue amounted to SEK 28 billion. Sobi’s share (STO:SOBI) is listed on Nasdaq Stockholm.

Contacts

Visiting address

Norra Stationsgatan 93A, Stockholm

+46 8 697 20 00
info@sobi.com

Gerard Tobin

Head of Investor Relations

gerard.tobin@sobi.com

Quotes

The positive pozdeutinurad readout in gout is a key milestone that highlights its potential in gout treatment, supports our upcoming launch trajectory, and reinforces confidence in continued progress through 2026 and beyond.

Guido Oelkers, President & CEO

We started 2026 with a strong business performance driven by the continued launch success of Altuvoct and Gamifant. Additionally, we made significant advances with our pipeline with the launch of Aspaveli in C3G and IC-MPGN, and the filing of Tryngolza in sHTG in Europe.

Guido Oelkers, President & CEO

We have delivered significant results in the business in 2025 and importantly made tremendous progress with our pipeline setting Sobi up for significant longer term growth potential. We look forward with excitement to bringing these medicines to more and more people in need of innovative treatments.

Guido Oelkers, President & CEO

We delivered strong quarterly results and achieved 16 per cent revenue growth at CER demonstrating the strength of our portfolio. In 2025, we made significant advances with our pipeline, highlighted by the regulatory submissions of Aspaveli, and NASP, the pivotal read out of Tryngolza in sHTG and the agreement to acquire Arthrosi Therapeutics in order to strengthen our gout franchise.

Guido Oelkers, President & CEO

For the quarter, our business accelerated and achieved 21 per cent growth at CER demonstrating the strength of our portfolio. We also advanced our pipeline with the US filing acceptance for NASP in uncontrolled gout and the preparations for a new opportunity for olezarsen in severe hypertriglyceridemia, both expected to contribute significantly to long-term growth.

Guido Oelkers, President & CEO

Pick a time period -

Tags ( Active)

All Regulatory Non-Regulatory

Sobi™ initiates disclosure of payments to the healthcare industry to increase transparency

Tue, May 31, 2016 14:00 CET

Swedish Orphan Biovitrum AB (publ) (Sobi™) today announced that the company has started implementing the European Federation of Pharmaceutical Industries and Associations (EFPIA) Disclosure Code to make all payments and transfers of value to healthcare professionals and organisations from 2015 publicly available, including sponsorships to attend meetings, speaker fees, consultancy and advisory boards. The information will be made available on Sobi´s corporate web site, starting 31 May 2016. The implementation of the EFPIA Disclosure Code is an important part of

There are no items matching the current filter

There are no more items matching the current filter

Share

About Us

Contacts

Quotes

Sobi™ initiates disclosure of payments to the healthcare industry to increase transparency

Subscribe